MAP2K7 and pachyonychia congenita: This may also include other combination applications in PC, such as the recent combination of FAKi with immunotherapy or mitogen-activated protein kinase kinase (MEK) inhibition in PC in which administration of multiple drug combinations and chronic treatment can serve as a bottleneck or a limitation for patient treatment in this disease (8, 15, 53, 69, 70).